ZOLADEX® 3.6 mg

DRUG3 trials

Sponsors

Luye Pharma Group Ltd.

Conditions

Breast CancerProstate Cancer

Phase 1

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

CompletedNCT05140512

Luye Pharma Group Ltd.Prostate Cancer

Start: 2021-02-04End: 2021-11-26Updated: 2023-05-16

Phase 3

Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

CompletedNCT04563936

Luye Pharma Group Ltd.Prostate Cancer

Start: 2020-01-06End: 2021-03-09Updated: 2021-08-26

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

CompletedNCT05110170

Luye Pharma Group Ltd.Breast Cancer

Start: 2020-10-15End: 2022-06-24Updated: 2023-05-16

Related Papers

Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial

Chinese Medical Journal2023-04-035 citations